AbbVie (NYSE:ABBV) Stock Price Down 1.5% – Here’s What Happened

AbbVie Inc. (NYSE:ABBV)’s stock price was down 1.5% during trading on Friday . The stock traded as low as $255.58 and last traded at $256.27. Approximately 4,679,176 shares traded hands during trading, a decline of 30% from the average session volume of 6,685,035 shares. The stock had previously closed at $260.21.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Bank of America raised their price objective on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a report on Friday, July 10th. UBS Group lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Guggenheim upped their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Piper Sandler raised their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $275.95.

AbbVie Trading Down 1.5%

The company has a market capitalization of $452.78 billion, a PE ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29. The company has a fifty day simple moving average of $254.66 and a 200-day simple moving average of $230.06.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the firm earned $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insider Activity at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

A number of hedge funds have recently modified their holdings of the business. Parkside Financial Bank & Trust lifted its position in AbbVie by 2.2% in the second quarter. Parkside Financial Bank & Trust now owns 29,261 shares of the company’s stock valued at $7,363,000 after buying an additional 630 shares during the last quarter. Kinetic Wealth Investment Advisors LLC acquired a new stake in shares of AbbVie during the second quarter valued at about $298,000. Range Advisory LLC increased its position in shares of AbbVie by 88.9% during the second quarter. Range Advisory LLC now owns 5,721 shares of the company’s stock valued at $1,440,000 after acquiring an additional 2,692 shares during the last quarter. Capital & Planning LLC raised its stake in shares of AbbVie by 21.5% in the 2nd quarter. Capital & Planning LLC now owns 19,416 shares of the company’s stock valued at $4,886,000 after acquiring an additional 3,430 shares during the period. Finally, Brown Lisle Cummings Inc. raised its stake in shares of AbbVie by 0.5% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 28,996 shares of the company’s stock valued at $7,296,000 after acquiring an additional 139 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.